Abemaciclib

Overview

Abemaciclib is an orally administered selective inhibitor of cyclin-dependent kinases 4 and 6, which are key regulators of the cell cycle. It is primarily used in the treatment of hormone receptor-positive, HER2-negative breast cancer.

API suppliers (1)

Suppliers of Abemaciclib backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• MSN Laboratories Private LimitedIndia2 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (4 approved US products), the latest listed US patent on Abemaciclib expires 27 Sept 2031. Generic API sourcing typically opens up once these lapse.

Therapeutic areas